Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Internet Based Vascular Risk Factor Intervention and Self Management Study (IRIS)

13. juni 2012 opdateret af: dr.Frank L.J. Visseren, UMC Utrecht

Internet-based Vascular Risk Factor Management for Patients With Clinical Manifest Vascular Disease; a Randomized Controlled Trial

The objective of the study is to evaluate the efficacy and cost-effectiveness of an internet based vascular risk factor program on top of usual care compared to usual care alone for treatment of vascular risk factors in patients at high risk for new vascular events.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

The objective of the study is to evaluate the efficacy and cost-effectiveness of an internet based vascular risk factor program on top of usual care compared to usual care alone for treatment of vascular risk factors in patients at high risk for new vascular events.

Study design: randomized non-blinded trial Study population: patients in the Rijnstate Hospital Arnhem and the UMC Utrecht, The Netherlands with a recent diagnosis of cerebral, cardiac or peripheral artery disease that entered the risk factor screening programs in these hospitals revealing 2 or more treatable risk factors.

Intervention: After the screening program patients will be randomized to usual care alone or to the internet program on top of usual care. Usual care for risk factor management will be delivered by the medical specialist and/or the general practitioner. Patients randomized to the internet based intervention program are first seen by the nurse practitioner on a regular clinic visit. The internet dossier is than created and explained to the patient. Subsequent contacts between nurse practitioner and patient about risk factor management is mainly by the internet. The nurse practitioner works according to the national guidelines for cardiovascular risk management ('CardioVascular Risico Management 2006') and is supervised by an internist. The study period is 1 year. All patients in both groups ware asked to return to the clinic for a follow up measurement of risk factors after 1 year.

Outcome measures: Primary outcome is the difference in Framingham heart risk score between baseline and after 1 year. As secondary outcome the percentage of patients achieving treatment goals for each risk factor and the average change in the absolute value of each risk factors after 1 year will be used.

Sample size calculation/data analysis: 380 patients. Changes in risk factors (absolute change and fraction of patients achieving treatment goal of each risk factor) at the start and after 1 year and between the groups are tested with independent sample t-test and Chi-square test.

Economic evaluation: The balance between costs and effects of the internet based vascular risk factor management program will be compared to usual care. Using a previously developed cardiovascular disease model incremental cost-utility analyses will be conducted with remaining life expectancy as the relevant time horizon.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

330

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Arnhem, Holland, 3508 GA
        • Rijnstate Hospital
      • Utrecht, Holland, 3584 CX
        • Department of Vascular Medicine UMC Utrecht

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participation in a cardiovascular risk screening program
  • 2 or more modifiable risk factors not on target:
  • SBP > 140 mmHg
  • LDL-c > 2.5 mmol/l
  • Triglycerides > 1.7 mmol/l
  • BMI > 25 kg/m2
  • Diabetes Mellitus or fasting glucose > 6.1 mmol/l
  • Smoking

Exclusion Criteria:

  • No internet access at home
  • Unable to read and write Dutch
  • Dependent in in daily activities (Ranking score >=3)
  • Life expectancy < 2 years or an active malignant disease

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: internet based intervention
The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
Andre navne:
  • praktiserende sygeplejerske
  • selvkontrol
  • primære sundhedssektor
  • Disease management
  • internet
  • risk factors
  • vascular diseases
Ingen indgriben: usual care
Patients receive their usual care from their specialist or general practitioner.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Framingham heart risk score
Tidsramme: 1 year
1 year

Sekundære resultatmål

Resultatmål
Tidsramme
Percentage of patients achieving treatment goals for each risk factor
Tidsramme: 1 year
1 year
Additional costs per additional patient achieving treatment goal
Tidsramme: 1 year
1 year
Cost per life year gained, cost per QALY
Tidsramme: 1 year
1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Frank Visseren, MD PhD, UMC Utrecht
  • Studiestol: Yolanda van der Graaf, MD PhD, Julius Center for Health Sciences and Primary Care
  • Studiestol: Ardine de Wit, MD PhD, Julius Center for Health Sciences and Primary Care
  • Studiestol: Karin Kaasjager, MD PhD, Rijnstate Hospital Arnhem

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. oktober 2008

Primær færdiggørelse (Faktiske)

1. marts 2011

Studieafslutning (Faktiske)

1. juni 2011

Datoer for studieregistrering

Først indsendt

4. november 2008

Først indsendt, der opfyldte QC-kriterier

4. november 2008

Først opslået (Skøn)

5. november 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

14. juni 2012

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. juni 2012

Sidst verificeret

1. juni 2012

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 80-00702-98-084 ZonMw
  • 08-119/O (Anden identifikator: METC UMC Utrecht)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner